Comprehensive non-small cell lung cancer targets: From computational prediction to clinical breakthroughs in...

Area of Science:

• Oncology
• Pharmacology
• Computational Biology

Background:

• Non-small cell lung cancer (NSCLC) is a major cause of cancer mortality, with conventional treatments showing limitations.
• There is a critical need for more effective and less toxic targeted therapies for NSCLC.
• Recent progress in understanding NSCLC biology and drug resistance mechanisms drives therapeutic innovation.

Purpose of the Study:

• To review state-of-the-art target prediction methodologies in NSCLC.
• To examine clinical advancements in targeting oncogenic drivers and overcoming drug resistance.
• To discuss combination therapies and future research directions for NSCLC.

Main Methods:

• Integration of ligand-based, structure-based, and deep learning models for target prediction.
• Analysis of clinical data for tyrosine kinase inhibitors (e.g., amivantamab) and resistance mutations (e.g., T790M, C797S).
• Review of combination regimens (e.g., osimertinib with savolitinib) and synthetic lethality approaches.

Main Results:

• Advanced computational models enhance NSCLC target identification and validation.
• Fourth-generation EGFR inhibitors show promise, but drug resistance remains a challenge.
• Combination therapies demonstrate synergistic effects, improving clinical outcomes by inhibiting compensatory pathways.

Conclusions:

• Targeted therapies and combination regimens represent significant progress in NSCLC treatment.
• Addressing drug resistance through novel strategies like synthetic lethality is crucial.
• Future efforts should focus on multi-target therapeutics and AI-driven drug discovery for NSCLC.